ClinicalTrials.gg
CompletedNCT06197243Updated Sep 30, 2026Results posted

Augmenting Benzodiazepine Receptor Agonist Deprescribing With Acupuncture and Yoga Among Older Adults

An interventional study of Acupuncture and Yoga in Anxiety, Insomnia and Benzodiazepine, sponsored by Vanderbilt University Medical Center. Completed at 1 site in United States. Open to participants aged 65 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-09-30.

Primary conditionSleep Initiation and Maintenance DisordersRegistry: Anxiety DisordersReclassifiedWhy we changed it
Registry
Anxiety Disorders — the first condition term the registry derived for this study.
ClinicalTrials.gg
Sleep Initiation and Maintenance Disorders
Why
  1. The registry often attaches Anxiety Disorders to studies about something else, and this study's title and listed conditions do not name it.
  2. The study's listed conditions name Sleep Initiation and Maintenance Disorders.
Confidence
High: the new condition is named in the study's own listed conditions. Of 351 hand-checked studies reclassified this way, 68% were exactly right and 84% in the right disease family; the registry's first term was right for 5% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by Vanderbilt University Medical Center · Not applicable, Interventional, and Treatment

How we know

Updated Sep 30, 2026Results postedStudy documents posted+1 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
23
Allocation
Not applicable
Ages
65 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 907 studies in Sleep Initiation and Maintenance Disorders with a site in United States — 149 open to participants now, 186 under way, 5 of them phase 3. Sleep Initiation and Maintenance Disorders · United States.

Enrollment
685th of 858
23 · median 60
Started
2023
with 61 others
No phase
580 of 907
110 open now
Registered
730th of 907
by date

Among the 907 studies in Sleep Initiation and Maintenance Disorders with a site in United States, this one is the 685th largest by enrollment of the 858 interventional ones that give a count, is one of 62 that started in 2023, is one of 580 with no phase, and was the 730th registered.

Sleep Initiation and Maintenance Disorders

2,738 studies on the registry are indexed under Sleep Initiation and Maintenance Disorders; 735 are open to participants now.

Browse Sleep Initiation and Maintenance Disorders studies →

Open to participants now

149 of the 907 studies in Sleep Initiation and Maintenance Disorders with a site in United States are open now. Recruiting first, the newest first:

144 more — sign in →

All 149 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 394 Sleep Initiation and Maintenance Disorders studies recruiting now, 156 (40%) set no upper age limit and 208 (53%) stop at 75 or younger; 61 take children under 18; 112 take healthy volunteers.

This study: 65 Years and older · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 907 studies in Sleep Initiation and Maintenance Disorders with a site in United States, or all of them as a file.
02

Study summary

The main purpose of this 12-week study is to see if a new combination of treatments can help older adults reduce benzodiazepine or related medication use. The treatment combination consists of 1) medical provider visits to gradually reduce the medication dose over 12 weeks, 2) acupuncture treatments, and 3) private yoga classes. Participants will be offered weekly visits for 12 weeks to receive combined treatments. Participants will be provided surveys before, during, and after the study to learn about their experience of the treatments. At the end of the study, participants will be invited to participate in a focus group to learn about their experience in the study.

Read the detailed description

This study consists of a single-arm clinical study among 30 older adults taking benzodiazepine receptor antagonists (BRZA) to assess the feasibility of protocol-driven BRZA deprescribing augmented with combined acupuncture and yoga. Adults 65 years or older that are taking BRZA will be recruited. Deprescribing will be provided at weekly visits with a psychiatric nurse practitioner at the Osher Center for Integrative Health at Vanderbilt University Medical Center. Participants will receive acupuncture and yoga from a staff acupuncturist and yoga instruction from a yoga instructor at the Osher Center. Feasibility of study enrollment will occur through the study enrollment period. Feasibility of study treatments will be evaluated during and after study treatment delivery. Feasibility of study outcome assessments will occur at baseline, 4, 8, and 12 weeks. Throughout the research process, investigators will engage a Stakeholder Advisory Panel consisting of patients and clinicians.

03

Conditions studied

  • Anxiety
  • Insomnia
  • Benzodiazepine
  • Deprescription

Browse trials for

04

In context

Sleep Initiation and Maintenance Disorders Reclassified

2,738 studies on the registry are indexed under Sleep Initiation and Maintenance Disorders; 735 are open to participants now.

This study's enrollment of 23 is below the median of 68 across 2,363 interventional studies indexed under Sleep Initiation and Maintenance Disorders.

Browse Sleep Initiation and Maintenance Disorders studies →

Lead sponsor

Vanderbilt University Medical Center is the lead sponsor of 837 studies on the registry; 157 are open to participants now.

Of its 126 completed or terminated interventional studies of FDA-regulated products, 92 (73%) have results posted.

Compared within Sleep Initiation and Maintenance Disorders, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Anxiety Disorders. The counts are of registry records indexed under each term, refreshed daily. How we classify →

05

Who can participate

Ages eligible
65 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • 65 years and older
  • Taking benzodiazepines or related medications (i.e. zolpidem, zopiclone, eszopiclone, zaleplon) at least 4 times in the last month
  • English speaking
  • Ability to understand study procedures and to comply with them for the length of the study

Exclusion criteria

Exclusion Criteria:

  • Cognitive impairment
  • Drinking more than 3 alcoholic beverages per day
  • Substance abuse disorder
  • Uncontrolled psychiatric disorder, such as major depression or psychosis
  • Inability or unwillingness of individual or legal guardian.representative to give written .
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

06

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
23 participants (actual)

Study arms

  • Experimental
    Feasibility, Adherence and Acceptability Measure

    Assay of feasibility of study enrollment and feasibility of study treatments, the latter of which is measured via fidelity, adherence, and acceptability of/to treatments and interventions. Interventions administered for 12 weeks. Fidelity, adherence, and acceptability will be measured via patient survey and engagement.

    Other: Acupuncture · Other: Yoga · Other: Deprescribing

Interventions

  • OtherAcupuncture

    Patients will receive acupuncture for 12 weeks.

  • OtherYoga

    Patients will receive yoga therapy with one of three yoga instructors. Patients will remain with singular yoga instructor for duration of study. It is anticipated that patients will participate in yoga therapy for 12 weeks at home and in-clinic.

  • OtherDeprescribing

    Deprescribing of patients' benzodiazepine use will be monitored by psychiatric nurse. Tapering method will be followed for medication deprescription.

07

What researchers measure

Primary outcomes

  1. BRZA Dose Change

    Dose of BRZA for patients will be measured at baseline and 12 weeks

    Time frame: Baseline to 12 weeks

Secondary outcomes

  1. Insomnia

    Will use Patient Reported Outcomes Measurement Information System(PROMIS) Sleep Disturbance Computerized Adaptive Testing to assess difficulties staying and falling asleep. The minimum value is 0 and the maximum value is 100, with higher scores determining worse outcomes.

    Time frame: Baseline to12 weeks

  2. Anxiety

    Will use Patient Reported Outcomes Measurement Information System(PROMIS) Anxiety Computerized Adaptive Testing. The minimum value is 0 and the maximum value is 100, with higher scores determining worse outcomes.

    Time frame: Baseline to 12 weeks

  3. Proportion of Participants Whom the Investigators Collect Primary and Secondary Outcomes.

    Will estimate feasibility of data collection for study measures by calculating proportion of participants whom the investigators collect primary and secondary outcomes.

    Time frame: Baseline to 12 weeks

08

Results

Posted Sep 30, 2026

Participant flow

Participant flow — Overall Study
MilestoneBenzodiazepine Receptor Agonist Deprescribing With Acupuncture and Yoga
Started23
Completed15
Not completed8
Withdrew: Withdrawal by subject8

Outcome measures

PrimaryBRZA Dose Change

Dose of BRZA for patients will be measured at baseline and 12 weeks

Time frame:
Baseline to 12 weeks
Reported as:
Mean · Benzodiazepine equivalents (mg)
BRZA Dose Change
Benzodiazepine equivalents (mg)Benzodiazepine Receptor Agonist Deprescribing With Acupuncture and Yoga
BRZA Dose Change-5.1 ± 7.6
SecondaryInsomnia

Will use Patient Reported Outcomes Measurement Information System(PROMIS) Sleep Disturbance Computerized Adaptive Testing to assess difficulties staying and falling asleep. The minimum value is 0 and the maximum value is 100, with higher scores determining worse outcomes.

Time frame:
Baseline to12 weeks
Reported as:
Median · Score on the scale
Insomnia
Score on the scaleBenzodiazepine Receptor Agonist Deprescribing With Acupuncture and Yoga
Insomnia-3.0 (-5.4 to -.1)
SecondaryAnxiety

Will use Patient Reported Outcomes Measurement Information System(PROMIS) Anxiety Computerized Adaptive Testing. The minimum value is 0 and the maximum value is 100, with higher scores determining worse outcomes.

Time frame:
Baseline to 12 weeks
Reported as:
Median · Score on a scale
Anxiety
Score on a scaleBenzodiazepine Receptor Agonist Deprescribing With Acupuncture and Yoga
Anxiety-2.8 (-7.4 to 1.1)
SecondaryProportion of Participants Whom the Investigators Collect Primary and Secondary Outcomes.

Will estimate feasibility of data collection for study measures by calculating proportion of participants whom the investigators collect primary and secondary outcomes.

Time frame:
Baseline to 12 weeks
Reported as:
Number · Percentage
Proportion of Participants Whom the Investigators Collect Primary and Secondary Outcomes.
PercentageBenzodiazepine Receptor Agonist Deprescribing With Acupuncture and Yoga
Proportion of Participants Whom the Investigators Collect Primary and Secondary Outcomes.100

Adverse events

Collected over Enrollment up to 12 weeks. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Benzodiazepine Receptor Agonist Deprescribing With Acupuncture and Yoga0/23 (0%)0/23 (0%)0/23 (0%)

Baseline characteristics

Age, Categorical
Age, Categorical(Participants)Benzodiazepine Receptor Agonist Deprescribing With Acupuncture and Yoga
<=18 years0
Between 18 and 65 years0
>=65 years23
Sex: Female, Male
Sex: Female, Male(Participants)Benzodiazepine Receptor Agonist Deprescribing With Acupuncture and Yoga
Female16
Male7
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Benzodiazepine Receptor Agonist Deprescribing With Acupuncture and Yoga
American Indian or Alaska Native0
Asian1
Native Hawaiian or Other Pacific Islander0
Black or African American0
White22
More than one race0
Unknown or Not Reported0
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Benzodiazepine Receptor Agonist Deprescribing With Acupuncture and Yoga
Hispanic or Latino0
Not Hispanic or Latino23
Unknown or Not Reported0
09

Study locations

1 site
  • Osher Center for Integrative Health at Vanderbilt
    Nashville, Tennessee 37203, United States
10

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

11

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Dec 2023 to primary completion in May 2025, 17 months.

Results were first posted in Sep 2026, 1 year 4 months after primary completion.

Of 1,219 non-industry interventional studies with no phase under Sleep Initiation and Maintenance Disorders, half reached primary completion within 15 months of starting (the median), counting those still running; a quarter within 6 and three quarters within 35. This study's 17 months is above that.

Counting every sponsor, half of 1,297 studies reached it within 15 months; a quarter within 6 and three quarters within 34.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 26, 2023
First posted
Jan 9, 2024
StartActual
Dec 14, 2023
Primary completionActual
May 23, 2025
CompletionActual
May 23, 2025
Results first posted
Sep 30, 2026
Last update
Sep 30, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Results
Results posted
posted Sep 30, 2026
Primary outcomes
1 edited
What changed in the outcomes
  • EditedBRZA dose changeDose ChangeTime frame: Baseline to 12 weeks
Sep 30, 2026
Documents
Secondary outcomes
1 edited
What changed in the outcomes
  • EditedProportion of participants whomParticipants Whom the investigators collect primaryInvestigators Collect Primary and secondary outcomesSecondary Outcomes.Time frame: Baseline to 12 weeks
Sep 30, 2026
Show all 1 update
  1. Sep 30, 2026
    Results posted
    Primary outcomes 1 edited
    What changed in the outcomes
    • EditedBRZA dose changeDose ChangeTime frame: Baseline to 12 weeks
    Secondary outcomes 1 edited
    What changed in the outcomes
    • EditedProportion of participants whomParticipants Whom the investigators collect primaryInvestigators Collect Primary and secondary outcomesSecondary Outcomes.Time frame: Baseline to 12 weeks
    + 3 other changes: index terms, verification date and registry notes

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

12

Registry details

Key details

Study ID
NCT06197243
Responsible party
Gurjeet Birdee (Director, Osher Center for Integrative Health Department of Physical Medicine and Rehabilitation, Vanderbilt University Medical Center) — Principal investigator
First posted
Jan 9, 2024
Start date
Dec 14, 2023
Primary completion
May 23, 2025
Completion
May 23, 2025
Results posted
Sep 30, 2026
Last update
Sep 30, 2026

Study contacts

Gurjeet Birdee
principal investigator · Vanderbilt University Medical Center

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion